Uveitis Etiology in China: A Systematic Review and Meta-Analysis.

Semin OphthalmolJun 17, 2026 (epub)
Clinical ResearchOphthalmology

Tom Liba, Tal Elkobi, Alon Gorenshtein et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the etiological profile of uveitis in China, analyzing data from 10 studies published between 2005 and 2025. The results indicated that idiopathic uveitis accounted for 41.75% of cases, with significant contributions from autoimmune conditions such as Vogt-Koyanagi-Harada syndrome (14.12%) and Behçet's disease (7.7%).

Key findings

  • Idiopathic uveitis was the most common cause, accounting for 41.75% of cases.
  • Vogt-Koyanagi-Harada syndrome represented 14.12% of uveitis cases.
  • Behçet's disease was identified in 7.7% of cases.
  • Infectious causes were less common, with herpetic uveitis at 2.22%.

Why it matters

Understanding the etiological distribution of uveitis in different populations can guide clinicians in diagnosis and management, particularly in regions with distinct epidemiological profiles like China.

Source

PubMed · PMID 42304964

Published in Semin Ophthalmol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.